𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival

✍ Scribed by José A. López-Guerrero; Antonio Llombart-Cussac; Rosa Noguera; Samuel Navarro; Antonio Pellin; Sergio Almenar; Carlos Vazquez-Alvadalejo; Antonio Llombart-Bosch

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
246 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The authors analyzed the HER2 status in early‐stage nonrecurrent and recurrent breast cancer groups following breast‐conserving treatment. Retrospective analyses of a group of 36 invasive early breast cancer (IBC) patients who developed a local recurrence as a first event and of a random control group of 69 IBC patients were made. HER____2 status was assessed by the HercepTest® (Dako Corp., Carpinteria, CA) and fluorescence in situ hybridization. The Kaplan–Meier proportional log‐rank test was used to study the impact of the biological factors on the metastasis‐free interval (MFI) and the overall survival (OS). The Cox proportional hazards model, using stepwise selection was performed to identify the independent predictors of poor outcome. The median time of follow‐up was 156 months (range: 22–230) for the nonrecurrent group of patients and 119 months (range: 36–228) for the recurrent group. No significant differences between either group were observed in terms of either patient or tumor characteristics, or of HER2 expression. However, a higher proportion of HER____2 amplified cases were found in the recurrent group, in contrast to a higher proportion of hormonal receptor positive cases in the nonrecurrent group. After univariate and multivariate analyses, HER____2 amplification was found to be an independent predictive factor for distant metastasis (HR = 10.75; p = 0.00008) and for survival (HR = 4.22; p = 0.004). In conclusion, HER____2 amplification constitutes an independent poor prognostic factor for the MFI and OS in patients with recurrent breast cancer. The clinical implications are discussed. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Does local recurrence affect the rate of
Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?
✍ Frank A. Vicini; Larry Kestin; Raywin Huang; Alvaro Martinez 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current analysis was to evaluate the impact of local recurrence (LR) on the development of distant metastases (DM), overall survival (OS), and cause specific survival (CSS) in patients with early‐stage breast carcinoma who underwent conservative surgery

Association of C-erbB-2 protein over-exp
Association of C-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
✍ Olli-P. Kallioniemi; Kaija Holli; Tapio Visakorpi; Timo Koivula; Heikki H. Helin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 818 KB

## Abstract C‐__erb__B‐2 protein over‐expression was studied immunohis‐tochemically in 319 paraffin‐embedded breast carcinomas representing 89% of all breast‐cancer cases operated in the Tampere University Hospital between 1977 and 1981. The immunohistochemical evaluation of c‐__erb__B‐2 was optimi